<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Levocetirizine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Levocetirizine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Levocetirizine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11981" href="/d/html/11981.html" rel="external">see "Levocetirizine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13065" href="/d/html/13065.html" rel="external">see "Levocetirizine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5183881"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Allergy Relief [OTC];</li>
<li>Xyzal Allergy 24HR Childrens [OTC];</li>
<li>Xyzal Allergy 24HR [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F5183883"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Histamine H<sub>1</sub> Antagonist;</li>
<li>
                        Histamine H<sub>1</sub> Antagonist, Second Generation;</li>
<li>
                        Piperazine Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F5184440"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54680997-14b0-467f-9b8c-4cb52605d7f8">Allergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis (OTC only):</b>
<b>Oral:</b> 5 mg once daily (in the evening); some patients with less severe symptoms may experience relief with 2.5 mg once daily; maximum dose: 5 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f65880a4-134b-4d60-99af-28a6f3dd6eaa">Urticaria, new onset and chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, new onset (off-label use) and chronic spontaneous (labeled use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>New onset: Oral:</b> Initial: 5 mg once daily. If symptom control is inadequate, may immediately increase to 5 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Asero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Asero.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic spontaneous: Oral:</b> Initial: 5 mg once daily. If symptom control is inadequate, may increase in 5 mg/day increments every 1 to 4 weeks up to 10 mg twice daily; periodically reevaluate necessity for continued treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29336054','lexi-content-ref-Khan.2021','lexi-content-ref-20226302']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29336054','lexi-content-ref-Khan.2021','lexi-content-ref-20226302'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990482"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">CrCl &gt;80 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 50 to 80 mL/minute: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 50 mL/minute: 2.5 mg once every other day.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 10 to 30 mL/minute: 2.5 mg twice weekly (every 3 or 4 days).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;10 mL/minute: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Nondialyzable (&lt;10% with 4-hour dialysis session): Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Use is contraindicated (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50987643"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. </p></div>
<div class="block doe drugH1Div" id="F5184441"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; dosing should begin at the lower end of the dosing range. </p></div>
<div class="block dop drugH1Div" id="F5184439"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13065" href="/d/html/13065.html" rel="external">see "Levocetirizine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c8123d5-63e1-4fd0-b4d4-fd52eac80de3">Allergic rhinitis, perennial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, perennial:</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children ≤5 years: 1.25 mg once daily (in the evening); maximum daily dose: 1.25 mg/<b>day</b>; <b>Note:</b> In children &gt;2 years, dosing based on previous FDA approved manufacturer labeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-UCB.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-UCB.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: <b>Note:</b> Dosing based on previous FDA approved manufacturer labeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-UCB.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-UCB.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 11 years: 2.5 mg once daily (in the evening); maximum daily dose: 2.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">≥12 years: 5 mg once daily (in the evening); some patients may experience relief of symptoms with 2.5 mg once daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="843156cb-cdeb-4737-abdb-0f34e3cbb69a">Hay fever and other respiratory allergies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hay fever and other respiratory allergies: OTC labeling: </b>Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: 1.25 mg once daily (in the evening); maximum daily dose: 1.25 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: 2.5 mg once daily (in the evening); maximum daily dose: 2.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 2.5 to 5 mg once daily (in the evening); dose based on symptom severity; maximum daily dose: 5 mg/<b>day </b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15368e67-78b2-46ad-bd4e-b23ab39acc64">Urticaria, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, chronic:</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children ≤5 years: 1.25 mg once daily (in the evening); maximum daily dose: 1.25 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: 2.5 mg once daily (in the evening); maximum daily dose: 2.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 5 mg once daily (in the evening); some patients may experience relief of symptoms with 2.5 mg once daily</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117847"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic</b>
<b> perennial rhinitis, chronic urticaria: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children ≤11 years: Contraindicated with any degree of renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;80 mL/minute: No adjustment necessary</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to 80 mL/minute: 2.5 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute: 2.5 mg once every other day</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 30 mL/minute: 2.5 mg twice weekly (every 3 or 4 days)</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute or on hemodialysis: Contraindicated</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Nondialyzable</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hay fever and other respiratory allergies (OTC)</b>: Children ≥2 years and Adolescents: Use is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F51117848"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants ≥6 months, Children, and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F5184414"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (infants: 13%; children: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Drowsiness (3% to 6%), fatigue (adolescents and adults: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (infants: 7%), vomiting (4%), xerostomia (adolescents and adults: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (children: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (adolescents and adults: 4% to 6%), cough (children: 3%), epistaxis (children: 2%), pharyngitis (adolescents and adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Neuromuscular &amp; skeletal: Weakness</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Aggressive behavior, agitation, anaphylaxis, angioedema, arthralgia, blurred vision, depression, dizziness, dysgeusia, dyspnea, dysuria, edema, febrile seizures, fixed drug eruption, hallucination, hepatitis, hypersensitivity reaction, increased appetite, increased serum bilirubin, increased serum transaminases, insomnia, movement disorder (including dystonia and oculogyric crisis), myalgia, nausea, nightmares, palpitations, paresthesia, pruritus, seizure, skin rash, suicidal ideation, syncope, tachycardia, tremor, urinary retention, urticaria, vertigo, visual disturbances, weight gain</p></div>
<div class="block coi drugH1Div" id="F5183891"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to levocetirizine, cetirizine, or any component of the formulation; end-stage renal disease (CrCl &lt;10 mL/minute); hemodialysis; infants and children 6 months to 11 years of age with renal impairment</p></div>
<div class="block war drugH1Div" id="F5184411"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pruritus: Rebound pruritus has been reported within several days after stopping cetirizine, usually after long-term (eg, months to years) use; therefore, this may also occur with levocetirizine since it is the active enantiomer of cetirizine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Levocetirizine is excreted primarily by the kidneys; use with caution in adults with mild to severe renal impairment; dosage adjustments may be needed. Use is contraindicated in end-stage renal disease (CrCl &lt;10 mL/minute), patients undergoing hemodialysis, and in infants and children 6 months to 11 years of age with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention: Urinary retention may occur; use with caution in patients with increased risk of urinary retention (including spinal cord lesions or prostatic hyperplasia); discontinue if urinary retention occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878717"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).</p></div>
<div class="block foc drugH1Div" id="F5027664"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as dihydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyzal Allergy 24HR Childrens: 2.5 mg/5 mL (148 mL) [alcohol free, dye free, sugar free; contains methylparaben, propylparaben, saccharin; tutti-frutti flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/5 mL (118 mL, 148 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as dihydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief: 5 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyzal Allergy 24HR: 5 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p></div>
<div class="block geq drugH1Div" id="F5183882"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F6256223"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Levocetirizine Dihydrochloride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/5 mL (per mL): $0.62 - $1.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xyzal Allergy 24HR Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/5 mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Levocetirizine Dihydrochloride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.24 - $3.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Xyzal Allergy 24HR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F5184446"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer in the evening with or without food. Use an accurate measuring device for the oral solution; a household teaspoon is not an accurate measuring device.</p></div>
<div class="block admp drugH1Div" id="F52614250"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food in the evening.</p></div>
<div class="block use drugH1Div" id="F5027661"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis (OTC only):</b> Temporary relief of symptoms due to hay fever or other respiratory allergies (including rhinitis, sneezing, itchy/watery eyes, or itching of the throat/nose) in adults and pediatric patients ≥2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, perennial:</b> Relief of symptoms associated with perennial allergic rhinitis in pediatric patients 6 months to 2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, chronic spontaneous:</b> Treatment of uncomplicated skin manifestations of chronic spontaneous urticaria in adults and pediatric patients ≥6 months of age.</p></div>
<div class="block off-label drugH1Div" id="F56430952"><span class="drugH1">Use: Off-Label: Adult</span><p>Urticaria, new onset</p></div>
<div class="block mst drugH1Div" id="F5183880"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Levocetirizine may be confused with cetirizine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299591"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F5184421"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F5183887"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in nonpregnant females. Second generation antihistamines may be used for the treatment of allergic rhinitis and urticaria during pregnancy; however, information related to the use of levocetirizine in pregnancy is limited and other medications may be preferred (BSACI [Scadding 2017]; BSACI [Powell 2015]; Zuberbier 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Levocetirizine is the active enantiomer of cetirizine; refer to the cetirizine monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F5183890"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if levocetirizine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. When treatment of rhinitis and urticaria in breastfeeding women is needed, other agents are preferred (BSACI [Powell 2015]; BSACI [Scadding 2017]; Zuberbier 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Levocetirizine is the active enantiomer of cetirizine which is present in breast milk; refer to the cetirizine monograph for additional information.</p></div>
<div class="block mop drugH1Div" id="F5184448"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Creatinine clearance (prior to treatment for dosing adjustment)</p></div>
<div class="block pha drugH1Div" id="F5184427"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Levocetirizine is an antihistamine which selectively competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. Levocetirizine, the active enantiomer of cetirizine, has twice the binding affinity at the H<sub>1</sub>-receptor compared to cetirizine.</p></div>
<div class="block phk drugH1Div" id="F5184429"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 1 hour (Devillier 2008)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 hours (Devillier 2008)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and extensive</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Children 1 to 2 years: Oral solution: 0.37 ± 0.06 L/kg (Cranswick 2005); Children 6 to 11 years: Oral tablet: 0.4 ± 0.02 L/kg (Simons 2005); Adults:  ~0.4 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 91% to 92%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal (&lt;14%); via aromatic oxidation, N and O-dealkylation (via CYPA4), and taurine conjugation</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children 1 to 2 years: Oral solution: 4.09 ± 0.67 hours (Cranswick 2005); Children 6 to 11 years: Oral tablet: 5.7 ± 0.2 hours (Simons 2005); Adults: ~8 to 9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Children 1 to 2 years: Oral solution: Median: 1 hour (range: 1 to 6 hours) (Cranswick 2005); Children 6 to 11 years: Oral tablet: 1.2 ± 0.2 hours (Simons 2005); Adults: Oral solution: 0.5 hours, Tablet: 0.9 hours </p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (85.4 %); feces (12.9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Children 1 to 2 years: Oral solution: 1.05 ± 0.1 mL/minute/kg (Cranswick 2005); Children 6 to 11 years: Oral tablet: 0.82 ± 0.05 mL/minute/kg (Simons 2005); Adults: 0.63 mL/kg/minute  </p></div>
<div class="block phksp drugH1Div" id="F51198320"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with mild, moderate, severe renal impairment, and end-stage renal disease, the AUC increased by 1.8, 3.2, 4.3, and 5.7-fold, respectively, and the half-life increased by 1.4, 2, 2.9, and 4-fold, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Total body Cl was approximately 33% lower in 9 elderly subjects, compared with younger adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Half-life was slightly shorter in women than in men; however, the body weight-adjusted oral Cl in women appears to be comparable with that in men.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5027658"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Antallos | Evocet | Glencet | Glozal | L cet | Lazine | Levocet | Levozin | Omcet L | Relevo odt | Xyzal | Zolix</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alergical | Analerg | Atopix l | Cetimer L | Levomine | Supraler | Tiriz</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizin +pharma | Levocetirizin actavis | Levocetirizin Genericon | Levocetirizin hexal | Levocetirizin Krka | Levocetirizin Stada | Xyzall</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Xyzal</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acitrin L | Alcet | Cevozin | Clarigen | Curin | Lacer | Lce | Lecet | Lecetrin | Lerex | Levocet | Levotiz | Lingin | Liset | Lozin | Lvc | Megatrol | Netis | Polan | Purotrol | Rehaf | Rinocet | Rinotin | Seasonix | Sinacet | Verizin | Vocet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizin ab | Levocetirizin Teva | Levocetirizine actavis | Levocetirizine Apotex | Levocetirizine EG | Levocetirizine mylan | Levocetirizine ratiopharm | Levocetirizine sandoz | Xyzall</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Ceten l | Lazine | Levotriz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alercit | Bezaleria | Cezera | Ksivozan | L-cetiricon | Revistim | Xallergan | Xyzal | Zenaro</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dicloridrato de levocetirizina | Rizi | Vocety | Zina | Zyxem</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Allergo X | Levocet mepha allergie | Levocetirizin mepha | Levocetirizin Sandoz | Levocetirizin spirig hc | Xyzal</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Allergostop | Lazine | Levocetirizina Generis | Levotriz | Supraler | Xylix | Xyzall</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Degraler | Dofitex | Lezitar | Neo alertop | Xuzal | Zival</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Di min | Levocetirizine hydrochloride | Qi ping | Qiang yi | Xi ke xin | Xyzal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alerness | Antiss | Cehaler | Cetimer | Cetrilev | Expotizina | Glencet | Histadine | Lecetir | Levoc | Levocetirizina | Levodrine | Levopraz | Lezat | Rizin | Zyxem</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alergimed | Analergin neo | Cezera | Contrahist | Levocetirizin actavis | Levocetirizin biofarm | Levocetirizin Ratiopharm | Levocetirizine dr max | Levoxal | Volnostin | Xyzal | Zenaro</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Levoceti abz | Levocetirizin | Levocetirizin abz | Levocetirizin al | Levocetirizin beta | Levocetirizin ct | Levocetirizin fairmed | Levocetirizin hexal | Levocetirizin Micro Labs | Levocetirizin Ratiopharm | Levocetirizin Stada | Levocetirizine glenmark | Xusal | Xyzal | Xyzall</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alercrom | Alercure | Cetimer | Convenil | Elriz | Eurolevocet | Glencet | Lecefar | Lergical | Leskera | Levocetirizina | Levocetirizina if | Levotek | Neocet | Supraler | Tricevol aglf | Xalerg</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alerg letic | Alergiplus | Alerliv | Antiss | Berkaler | Cetimer | Degraler | Glencet | Levoc | Levocetirizina | Libbera | Lomazol | Neo alertop | Rinocet | Supraler | Zival</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cezera | Levocetirizine | Levocetirizine ratiopharm | Xyzal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Allear | Allevo | Lergicare | Lergopan | Levocitrone | Levoctivan | Levohistam | Modallerge | Orgitrizine | Xaltec | Zalkevor</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aralevo | Levocetirizina | Levocetirizina actavis | Levocetirizina apotex | Levocetirizina cInfa | Levocetirizina cinfamed | Levocetirizina Combix | Levocetirizina krka | Levocetirizina mylan | Levocetirizina normon | Levocetirizina pharma combix | Levocetirizina Sandoz | Levocetirizina stada | Levocetirizina tarbis | Levocetirizina Teva | Levocetirizina vegal | Muntel | Xazal</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">1 al | Histachek | Levocet | Levocetirizine | Levozal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Levazyr | Levocetirizin Ratiopharm | Levocetirizin Stada | Levocetirizine sandoz | Nocedan | Xyzal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizine | Levocetirizine actavis | Levocetirizine biogaran | Levocetirizine cristers | Levocetirizine EG | Levocetirizine evolugen | Levocetirizine KRKA | Levocetirizine mylan | Levocetirizine ranbaxy | Levocetirizine ratiopharm | Levocetirizine Teva | Levocetirizine Zentiva | Levocetirizine zydus | Xyzall</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizine | Xyzal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Contrahist | Levocet | Levocetirizine | Levocetirizine actavis | Levocetirizine glenmark | Xozal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alercet | Euro zysol | Leocet | Lerizine | Levocet | Levocezal | Levotil | Lisinex | Purotrol | Vick levozy | Xizyne | Xylaclear | Xyzal</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Xyzal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cetizal | Cezera | Histisynt | Lertazin | Levocep | Levocetirizin Hetero | Novocetrin | Pollezin | Sefaller | Xyzal | Zilola</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Avocel | Histrine levo | L falergi | Xyzal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizin Teva | Levocetirizine glenmark | Levocetirizine KRKA | Rinozal | Xyzal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">1 al | Adicure | Adliz | Airitis | Alcet | Alci | Aldbest | Alerfix | Alert L | Alertin | Alertriz | Alidil | Allelin | Allercet l | Allerhin l | Allermed | Allerzine-l | Allrite | Altin le | Alvergy | Alzene | Alzero | Aplev | Astrizine | Betawin Lc | Cefid l | Cerzin-L | Cetalore | Cetcip l | Cetcure lc | Cetfast | Cetiriz L | Cetley | Cetmet l | Cetoz-l | Cetrezol L | Cetriliv | Cetrina lv | Cetrite | Cetsafe | Cezlevo | Cistin l | Covel | Criz | Daylong | Dicet l | Ekon-xl | Elate | Ele | Elriz | Elstar | Elycet | Elzin | Engecet | Ethizine | Fitin | Genlevo | Glc | Glencet | Hatric | Hhlevo | Hicet-l | His-block | Histachek | Histacross l | Ibalert 5 | Ibialert | Intriz 5 | Izi md | Klocet | L Arpicet | L atriz | L C T | L Cetron | L dio 1 | L zin | L-alerid | L-Cetramac | L-cetridoc | L-cetrizet | L-dio-1 | L-tine | Lah | Laveta | Lazine | Lc-5 | Lcet | Lcitzi | Lcz | Le one | Le zenrid | Le zyncet | Lecet | Lecope | Leday | Leecet | Lency | Leoriv | Lerzin | Leset | Lestal | Levalergy | Levo setride | Levocee | Levocet | Levocetrival | Levocetriwal | Levodil | Levohext | Levolar | Levoler | Levolyte | LevoMast | Levomer | Levonav | Levonitrin | Levoplan | Levorid | Levosetride | Levosiz | Levotiz | Levotrin | Levotrine | Levova | Lezet | Lezine | Lisani | Livacet | Livozine | Lod | Loviroc | Luvle | Lvt | Lyncet | Maxcet | Nexcet | Noarer | Novolev | Nucet | Nuzil | Occetiz | Okacet-l | Oriel | Palevo | Perizine | Primecet | Provent | Rezin l | Rizi | Rizin lc | Safecet | Sancet l | Sigcet | Starcet | Teczine | Thermal | Uvnil | Vcd | Verizet | Vibglow | Vocetin | Vociz | Votz | Vozet | Xenocet | Xevor | Xyzac | Xyzal | Zeez | Zilo | Zipcet | Zirlon L | Zocet | Zylera</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizina actavis | Levocetirizina doc generici | Levocetirizina EG | Levocetirizina fidia | Levocetirizina krka | Levocetirizina mylan | Levocetirizina pensa | Levocetirizina ranbaxy | Levocetirizina ratiopharm | Levocetirizina San | Levocetirizina Tev | Xyzal</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cetazal | L cet | Layal | Lesonal | Levozal | Xyzal | Zolix</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizine hydrochloride od nissin | Xyzal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alcet | Alerfree | Allerzine | Cetlevo | Ctz L | Enlev | Frecet | Glencet | Irnazin | Lazine | Leozin | Letrizine | Levocet | Levofast | Levohista | Levorid | Levotriz | Levozal | Maxcet | Xyzal | Zocet</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alcetin | Alcetizine | Alcitec | Alecet | Alecetin | Alefree | Alenan | Allecet | Allecetin | Allefree | Allenan | Allenex | Allerban | Allercetin | Allerin | Allerine | Allertop | Allerzal | Allezy | Altirizine | Altiz | Alvorin | Beartilin | Bicozal | Bizal | Boryung levocetirizine hydrochloride | Br ceti | Cellizin | Cenlevo | Cenova-L | Cetinal | Cetinzal | Cetirin | Cetirion | Cetizal | Cezal | Cipen | Citirizine | Cizaron | Cizin | Coalbi | Cocetin | Dialon | Eletine | Huniz levocetirizine hcl | Hyundai levocetirizine hcl | Intizine | Kaizal | Ketra | Ketrazin | Korus levocetirizine hydrochloride | L trizine | L-Tirizine | Lastrin | Lecer | Lecerin | Leceti | Lecetizal | Lecevo | Lecezal | Leptizine | Leti | Leticin | Letin | Letinin | Letirazine | Letirin | Letirizine | Letizal | Letizin | Letizine | Levoceltec | Levocen | Levocep | Levocera | Levocerin | Levocet | Levocetan | Levoceti | Levocetin | Levocetirin | Levocetirine | Levocetirizine | Levocetirizine 2hcl | Levocetirizine HanAll | Levocetrin | Levocezal | Levocezine | Levoconazine | Levocort | Levones | Levoq | Levorizin | Levotil | Levotirin | Levotizal | Levotizine | Levotop | Levotrizine | Levozal | Levozytec | Neocetin | Neorizine | Netizine | New ceretine | Newzal | Repcetin | Ribocetin | Samsung levocetirizine | Serenzal | Starizin | Xarlin | Xezal | Xyzal | Xyzin | Yuyu levocetirizine hcl | Zaltizine | Zarlin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Glozal | L cet | Levozin | Xyzal</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aralevo | Calivida | L Cit | Layal | Supraler | Xyzal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cezera | Levocetirizine actavis | Levocetirizine ratiopharm | Xyzal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizine EG | Xyzall</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizin actavis | Levocetirizine ratiopharm | Xyzal | Zenaro</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Allegra | Aplevax | Supraler | Xycet | Xyzall</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Belazix | Bocetix | Desceristad | Ergizar | Invoker | Komzimba | Lerpilex | Levigrix | Levocetirizina | Olenobran | Vazni | Xuceed | Xuzal | Zetyrel | Zyxem</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Avozine | Cetizal | Cezera | Egizin | Glencet | Lazine | Levocetirizine | Ranozine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Calivida | Cerizine | LCT</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cetirigen | Levocetirizine | Levocetirizine 2hcl actavis | Levocetirizine dihcl focus care | Levocetirizine diHCl Mylan | Levocetirizine diHCl PCH | Levocetirizine dihcl ratiopharm | Levocetirizine diHCL Sandoz | Xyzal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Xyzal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Levoclear | Levrix</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alerfix | Alerfort | Alergilab | Alergiplus | Alerliv | Cetriler | Degraler | Gazella | Histalex | Laboxet | Lctimax | Lergial | Lergizina plus | Lertamine | Lesstamin | Levo del | Levo luxergia | Levoallergy | Levocefar | Levocelip | Levocert | Levodif | Levogram | Levozalicer | Libbera | Libertium | Lizinaler | Lusaler | Quitaler | Rapiler | Sinalerg | Sprint | Xyzal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Allerzet | Coalbi | Getcet | Glencet | Histalev | L zet | Le zyncet | Lecetzy | Lerizine | Letrizine | Levocet | Levocetirizine | Levozyr | Lisinex | Nozal | Philcet | Purcet | Sensitrin | Stalevo | Tecovel | Veltir | Xylergic | Xyzal | Zocet</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alcivo | Alvozine | Atiza | Belair | Cerigex-l | Citrafast | Etrizine L | Evotex | Firax levo | Healazin l | Histamizine | Histaset | Hivocet | Invocet | Lcaria | Le vin | Lecetzi | Legozin | Leozin | Leridal | Letrazim | Leve cit | Leviva | Leviz | Levo Deebar | Levocet | Levocit | Levocitrin | Levomelt | Levopraz | Levota | Levozin | Lezet | Licet | Licide | Lirizine | Lixer | Neo sedil | Oakzine | Ocet | Ocitra | Okay | Relair | Selcet | Setrin | Setzine | Shavozin | T day | Velkeno | Voizin | Welcet | Xenocit | Xylizine | Xyzal | Zamocetrin | Zosper</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ahist | Cezera | Contrahist | Contrahist allergy | Lecetax | Levocedo | Levocetirizine dr.max | Levocetirizine Genoptim | Lirra | Lirra gem | Nossin | Votrezin | Xyzal | Zenaro | Zilola | Zyx</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Levocetirizine | Xyzal | Xyzal allergy 24hr</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Levocetiriz Bluefish | Levocetirizina | Levocetirizina actavis | Levocetirizina ciclum | Levocetirizina cInfa | Levocetirizina Fair Med | Levocetirizina Generis | Levocetirizina krka | Levocetirizina ratiopharm | Levocetirizina Sandoz | Levocetirizina tolife | Levocetirizina wynn | Levocetirizina Zentiva | Levrix | Rovinex | Xyzal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aleretic | Alermax | Degraler | Neo alertop | Nofludes | Novo alergina | Recifer | Zival</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Alerinit | Alezal | Glencet | L-Cet | Layal | Layal Syrup | Lesonal | Levar | Omcet-L | Xyzal</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cetizal | Cezera | Contrahist | Xyzal | Zenaro</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alercet l | Allerway | Cesera | Elcet | Glencet | Levocetirizin Teva | Levocetirizine | Levocetirizine sandoz | Levocetirizine vertex | Suprastinex | Xyzal | Zenaro | Zodac express</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Allercet | Glozal | L cet | Layal | Levozal | Levozin | Lezal | Xyzal | Zolix</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Allerzal | Levozine | Xyzal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cezera | Xyzal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alergimed | Cetizal | Cezera | Contrahist | Levocetirizin Dr.Max | Levocetirizin Ratiopharm | Levocetirizin Sandoz | Levocetirizin Teva | Levocetirizine actavis | Xyzal | Zenaro</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cetizal | Ellezin | Leres | Levocet | Levoside | Levtrizin | Xyzal | Zyller</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Allergy stop | Levorgica | Levostamine | Xylix | Xyzall</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alerinit | Crebros | Leviset | Vivid | Xyzal | Zenaro</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Beloton | Levocetirizine | Levozal | Levozine | Limino | Locemine | Minlo | Neocetin | Sorimine | Xyzal | Xyzalin | Xyzine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aleron | Alerzin | Allercet | Allergofree | Allergolik | Allerway | Cetlo | Cetrilev | Cetrilev neo | Cetrimac | Ergocetal | Glencet | L cet | Lazine | Levocetirizin astrapharm | Levosetil | Levzirin | Sezonia | Xyzal</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Fitin | Lazine | Levozin | Lezyncet | Welbeen l</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Histaplen | Levocet | Tiriz</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aplev | Cenaret | Cetimer | Glencet | Levocetirizina | Levorat</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Halez | Levnew | Levoagi | Levocozate | Levohistil | Ripratine | Xytab</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Allerway | Cetaway | Cetizal | Cetlev | Glencet | Levogex | Levoway | Texamer | Xyleve | Xyzal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. Available at http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Asero.1">
<a name="Asero.1"></a>Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24766875">
<a name="24766875"></a>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol</i>. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levocetirizine-drug-information/abstract-text/24766875/pubmed" id="24766875" target="_blank">24766875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levocetirizine-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15966463">
<a name="15966463"></a>Cranswick N, Turzíkova J, Fuchs M, et al. Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile.<i> Int J Clin Pharmacol Ther.</i> 2005;43(4):172-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levocetirizine-drug-information/abstract-text/15966463/pubmed" id="15966463" target="_blank">15966463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18336052">
<a name="18336052"></a>Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. <i>Clin Pharmacokinet.</i> 2008;47(4):217-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levocetirizine-drug-information/abstract-text/18336052/pubmed" id="18336052" target="_blank">18336052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.2021">
<a name="Khan.2021"></a>Khan DA. Chronic spontaneous urticaria: standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference">
                  Levocetirizine [prescribing information]. Congers, NY: Chartwell RX LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16083790">
<a name="16083790"></a>Simons FE and Simons KJ. Levocetirizine: Pharmacokinetics and Pharmacodynamics in Children Age 6 to 11 Years. <i>J Allergy Clin Immunol</i>. 2005;116(2):355-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levocetirizine-drug-information/abstract-text/16083790/pubmed" id="16083790" target="_blank">16083790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20226302">
<a name="20226302"></a>Staevska, M, Popov T, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. <i>J Allergy Clin Immunol</i>. 2010;125(3):676-682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levocetirizine-drug-information/abstract-text/20226302/pubmed" id="20226302" target="_blank">20226302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-UCB.1">
<a name="UCB.1"></a>Xyzal (levocetirizine) [prescribing information]. Smyrna, GA: UCB, Inc; January 2016.</div>
</li>
<li>
<div class="reference">
                  Xyzal (levocetirizine dihydrochloride) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis, US, LLC; April 2019.</div>
</li>
<li>
<div class="reference">
                  Xyzal Allergy 24HR (levocetirizine dihydrochloride) [prescribing information]. Chattanooga, TN: Chattem, Inc; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xyzal.4">
<a name="Xyzal.4"></a>Xyzal Children’s Allergy 24HR (levocetirizine dihydrochloride) [prescribing information]. Chattanooga, TN: Chattem Inc; received November 2022.</div>
</li>
<li>
<div class="reference">
                  Xyzal Children's liquid (levocetirizine dihydrochloride) [prescribing information]. Chattanooga, TN: Chattem, Inc.; February 2017.</div>
</li>
<li>
<div class="reference">
                  Xyzal Children's tablet (levocetirizine dihydrochloride) [prescribing information]. Chattanooga, TN: Chattem, Inc.; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336054">
<a name="29336054"></a>Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy</i>. 2018;73(7):1393-1414.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levocetirizine-drug-information/abstract-text/29336054/pubmed" id="29336054" target="_blank">29336054</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9443 Version 436.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
